This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

VaxGen Hits Anthrax Jackpot

It took quite some time, but VaxGen (VXGN) finally scored its big contract to supply an anthrax vaccine to the U.S. government. For VaxGen and its shareholders, the deal appears lucrative and its shares were recently up $3.23, or 22%, to $17.58. Volume was 5.5 million shares, or more than 12 times average.

The grand total of the contract: $877 million over five years, which the government will pay to VaxGen to manufacture and supply 75 million doses of the anthrax vaccine, which will be used to create a national stockpile to protect Americans against a possible terrorist attack. The funding for the contract comes under the auspices of the Project BioShield Act of 2004.

VaxGen has been working on landing this contract for more than two years. VaxGen switched its corporate focus to developing bio-terrorism vaccines after its much-ballyhooed AIDS vaccine failed a late-stage clinical study in February 2003.

On a conference call Friday morning, VaxGen said it expects to begin shipping anthrax vaccine to the government in early 2006, ending the year with 25 million doses shipped. At $11.70 per dose, that works out to $292 million in anthrax vaccine revenue for VaxGen in 2006.

The remaining 50 million doses -- worth $585 million -- will be delivered in 2007, the company said. In addition, VaxGen expects to earn $123 million in additional payments from the government in late 2007, based on the achievement of three milestones, including getting final approval from the Food and Drug Administration for the vaccine as well as meeting certain shelf-life standards.

For perspective, VaxGen is expected to generate about $40 million and $44 million in revenue in 2004 and 2005, respectively, primarily from ongoing government contracts. The company is not currently profitable.

VaxGen says its operating margins (earnings before interest and taxes) for the anthrax vaccine business will be in the range of 20% to 40%, comparable to its peers. At the midpoint of this range, or 30% margins on earnings before interest and taxes, VaxGen could conceivably generate operating income of nearly $90 million from the anthrax vaccine business alone in 2006 and $175 million in 2007.

Based on income projections similar to these, Ehrenkrantz King Nussbaum analyst Robert LeBoyer rates VaxGen outperform with a $26 price target. His firm doesn't have a banking relationship with the company.

CIBC analyst Matt Geller uses a discounted cash flow analysis of the expected revenue from the anthrax vaccine contract to come up with a $25 price target for VaxGen. He rates VaxGen overweight and his firm has a banking relationship with the company.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,787.43 +9.28 0.05%
S&P 500 2,063.73 +2.50 0.12%
NASDAQ 4,755.6260 +7.23 0.15%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs